International Journal of Cancer Management

Published by: Kowsar

Two Side Effects of Sutent Therapy in Renal Cell Carcinoma: A Case Report

Mehrdad Payandeh 1 , Edris Sadeghi 1 , * and Masoud Sadeghi 1
Authors Information
1 Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • International Journal of Cancer Management: April 2017, 10 (4); e4040
  • Published Online: March 20, 2017
  • Article Type: Case Report
  • Received: October 2, 2015
  • Revised: March 4, 2016
  • Accepted: March 7, 2017
  • DOI: 10.5812/ijcm.4040

To Cite: Payandeh M, Sadeghi E, Sadeghi M. Two Side Effects of Sutent Therapy in Renal Cell Carcinoma: A Case Report, Int J Cancer Manag. 2017 ;10(4):e4040. doi: 10.5812/ijcm.4040.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Acknowledgements
Footnotes
References
  • 1. Eivazi Ziaei J, Fakhrgoo A, Estakhri R. Gingival metastasis of renal cell carcinoma. Iran J Cancer Prev. 2011; 4(1): 44-7
  • 2. Edesa WA, Abdelmalek RR. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt. Asian Pac J Cancer Prev. 2015; 16(5): 1971-6[PubMed]
  • 3. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010; 40(10): 980-5[DOI][PubMed]
  • 4. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008; 26(22): 3763-9[DOI][PubMed]
  • 5. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J. 2007; 1(2 Suppl)-54[PubMed]
  • 6. Formiga MN, Fanelli MF. Aortic dissection during antiangiogenic therapy with sunitinib. A case report. Sao Paulo Med J. 2015; 133(3): 275-7[DOI][PubMed]
  • 7. Bragalone DL. Drug information handbook for oncology. 2011; : 1168-74
  • 8. Golledge J, Eagle KA. Acute aortic dissection. Lancet. 2008; 372(9632): 55-66[DOI][PubMed]
  • 9. Albiges L, Salem M, Rini B, Escudier B. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011; 25(4): 813-33[DOI][PubMed]
  • 10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(22): 3584-90[DOI][PubMed]
  • 11. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009; 20(9): 1535-42[DOI][PubMed]
  • 12. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(1): 16-24[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments